Drug intelligence / Profile preview

Tasectan Plus

Development stage: Unknown
Lead developer: Novintethical Pharma
Administration: Oral

Overview

Tasectan Plus is a medical device preparation developed by Novintethical Pharma for the treatment of acute diarrhea in both adults and children. It is a combination of xyloglucan, a plant-derived polysaccharide with film-forming properties, and gelatin. The product acts through a mechanical, non-pharmacological mechanism by forming a protective film over the intestinal mucosa. This barrier helps restore the physiological functions of the gut wall, protecting it against aggression from pathogens and toxins, thereby reducing the frequency and duration of diarrhea episodes. It is typically administered as oral capsules or sachets and has been studied in randomized clinical trials, including comparisons with diosmectite and Saccharomyces boulardii.

Brand names: Tasectan Plus
Other names: xyloglucan + gelatin

Beyond the preview

Go deeper on Tasectan Plus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tasectan Plus.

Explore the full profile